1. Introduction {#sec1}
===============

Non-communicable diseases (NCDs), the silent epidemic, are responsible for the majority of deaths in developed countries and their prevalence at a younger age was observed increasingly in the last years ([@bib291], [@bib292]). Cardiovascular disease (CVD), diabetes, obesity, cancer, Alzheimer\'s and Parkinson\'s disease, arthritis, non-alcoholic fatty liver disease (NAFLD) and chronic obstructive disease are some of the most common NCDs sharing common features. Research shows that redox impairments and chronic low-grade inflammation generate a vicious biochemical self-propagating cycle, constituting the molecular pathological root of these diseases. In the context of modern lifestyle, stress factors including malnutrition/overnutrition, smoking or sedentary routine are initiating factors for the impairment of inflammatory pathways contributing to the development of NCDs. Furthermore, in real-life scenarios, people experience uncontrolled simultaneous exposure to many environmental chemicals, hence novel methodological approaches simulating real-life exposures are being developed under the name real life risk simulation (RLRS) with the aim to assess the potential adverse health effects of long-term exposure to chemical mixtures ([@bib115]; [@bib117]; [@bib272], [@bib269]). According to WHO, 80% of NCDs-related deaths could be prevented by changes in these modifiable risk factors, and recent evidence identified unhealthy diet as the biggest risk factor for NCDs-related deaths ([@bib55]; [@bib292]).

Under physiological conditions, inflammation is a response to harmful stimuli (pathogens or tissue lesions), a cellular adaptive mechanism aiming to restore tissue homeostasis ([@bib181]). Inflammatory responses are self-limited through specific checkpoints that curb the progression and promote the resolution of inflammation ([@bib23]; [@bib250]). Failure due to the deleterious alterations of the inflammatory pathways brings about the excessive release of pro-inflammatory molecules, leading to chronic low-grade inflammation and fibrosis ([@bib207]; [@bib240]). The persistence of this usually short-term defence mechanism leads to a chronic inflammatory state, transitioning from solution to cause, becoming in fact a lesion-inducing factor for the affected tissues. This may be a result of the dysregulation of several cellular pathways involving cyclooxygenase-2 (COX-2), signal transducer and activator of transcription 3 (STAT3), matrix metalloproteinase-9 (MMP-9), nuclear factor kappa-B (NF-κB), cytokines with inflammatory outcome: interleukins (IL-1, IL-6, IL-8), tumour necrosis factor alpha (TNF-α), cell adhesion molecules and chemokines, etc. Of note, the resolution of the inflammatory process cannot be simply switched off by restricting the synthesis of the pro-inflammatory molecules, requiring cellular intervention through anti-inflammatory and pro-resolving molecules ([@bib184]; [@bib210]; [@bib248]).

Mitigating the pathological pathways associated with chronic low-grade inflammation through pharmacological agents but, more importantly, through diet and lifestyle changes might constitute an effective strategy in the prevention of NCD and NCD-related deaths. In the current review, we overview recent facts from molecular and animal studies to human clinical reports regarding the intricate pathways that are affected by some of our dietary habits, also discussing the next steps that ought to be taken in addressing these parameters.

2. Cellular and molecular inflammatory-related mechanisms {#sec2}
=========================================================

In physiological conditions, NF-κB (a heterotrimer with p65 and p50 subunits associated with the IκBα inhibitory subunit) is localized to the cytoplasm. Under the effect of inflammatory stimuli (for instance cytokines -- IL-8, IL-1β, IL-6, or TNF-α, UV exposure, etc), the heterodimer dissociates, IκBα is degraded, and the two components, p50 and p65, translocate into the nucleus binding the promoter regions from different genes that are involved in initiating several cellular pathways linked to chronic diseases, tumorigenesis, angiogenesis and metastasis. Among the genes regulated by NF-κB are the ones for the expression of TNF-α, COX-2, MMP-9, nitric oxide synthase -- the inducible form (iNOS), cytokines (IL-1, IL-6 and IL-8), 5-lipooxigenase (5-LOX), vascular endothelial growth factor (VEGF); all of these genes, when up-regulated fire-up the vicious circle constituted from oxidative stress and inflammation ([@bib1]; [@bib144]; [@bib153]; [@bib203], [@bib202]; [@bib224], [@bib225]; [@bib235]). Interestingly, the NF-κB cascade is also activated by some factors that affect the circadian rhythm, such as aging or sleep deprivation. In animal models, high-fat diets as well as obesity -- pro-inflammatory states, are directly correlated with a decrease of the amplitude of circadian activity and rhythmic gene expression, thus, suggesting that the inflammatory pathways are directly responsible for influencing the circadian clock ([@bib91]; [@bib148]; [@bib211]).

Another important inflammatory pathway involves STAT3, a cytoplasm protein that is phosphorylated by JAK 1, 2, and 3 (Janus-activated kinases), under the influence of inflammatory stimuli. STAT3 reaches the nucleus and functions as a transcriptional factor, stimulating the synthesis of inflammatory mediators ([@bib212]; [@bib260]). The MAPK/ERK (mitogen-activated protein kinases) group, including stress activated protein-kinases p38, JNK (c-Jun N-terminal kinases) and ERK (extracellular signal-regulated kinases), is also involved in the inflammatory cascade as a response to a detrimental stimulus ([@bib158]). Also, to the family of transcription factors we can comprise nuclear factor erythroid 2-related factor 2 (Nrf2), activator protein-1 (AP-1), nuclear factor of activated T cells (NFAT) or hypoxia-inducible factor-1α (HIF-1α), all being recognized for their role in stress response as well as in mediating inflammation ([@bib213]; [@bib235]) ([Fig. 1](#fig1){ref-type="fig"} ).Fig. 1Regulation of cellular pathways under the influence of pro-inflammatory stimuli (Keap1 -- Kelch-like ECH-associated protein 1; Cul3 -- Cullin 3; Nrf2 -- Nuclear factor erythroid 2-related factor 2; IKK -- IκB kinase; NF-κB -- Nuclear factor kappa-light-chain-enhancer of activated B cells heterodimer, consisting of p50, p65 and IkBα proteins; STAT3 -- Signal transducer and activator of transcription 3; ERK/MAPK -- mitogen-activated protein kinases; JNK -- c-Jun N-terminal kinases; MEK -- Mitogen-activated protein kinases kinase; HIFα -- Hypoxia-inducible factor α; HIFβ -- Hypoxia-inducible factor β; AP1 -- Activator protein 1, with its associated proteins cFOS - and cJUN; Maf -- Transcription factor Maf; ARE -- antioxidant response element).Fig. 1

Pro-inflammatory stimuli activate several regulatory cell processes. The activation of IKK (IκB kinase) causes the cleavage of NF-kβ, associated with nuclear translocation for p50 and p65, while that of MAPK directs the phosphorylation of p38, ERK and JNK. Also notable are the dimerization of STAT3 and the association of HIFα with HIFβ, all resulting in the activation of several transcription factors or direct stimulation of gene expression, targeting pro-inflammatory molecules. However, an increased expression of antioxidant enzymes can be encountered due to decreased degradation of Nrf2 and its activation of ARE, post-nuclear translocation and association with Maf. The activation of all the inflammation-related pathways, along the cellular and metabolic disturbances that follow, contributes to the high occurrence of obesity and associated pathology (diabetes mellitus, metabolic syndrome, CVD, Alzheimer\'s disease, etc), especially under the influence of modern life factors (malnutrition, smoking, pollution, low physical activity) ([@bib63]; [@bib95]; [@bib95]; [@bib105]; [@bib159]; [@bib278], [@bib279]; [@bib287]; [@bib304]). The obese state is characterized by low-grade systemic inflammation, with impaired synthesis of adipokines and activation of pro-inflammatory signalling pathways leading to insulin resistance. Adipose tissue inflammation is one of the determining factors of obesity complications, impairing the adipocyte secretory function and hormonal balance.

Physiologically, adipose tissue resident macrophages, displaying both a pro-inflammatory and anti-inflammatory phenotype, are involved in several housekeeping processes (differentiation of preadipocytes, abstraction of necrotic and apoptotic cells, angiogenesis adjustment, etc). The expansion of adipose tissue, due to long-lasting overnutrition, induces prolonged hypoxia (the activation of HIF-1α), and consequent inflammation as monocytes infiltrate in the hypoxic region and become pro-inflammatory macrophages, process during which TNF-α, monocyte chemotactic protein (MCP-1), IL-6, MMPs, IL-8, VEGF are released. Further, the inflammatory response elicited by dysfunctional adipocytes, hypoxia, adipocyte expansion, and impaired fatty acids storage is accelerated by formation of reactive species, either oxygen (ROS) or nitrogen (RNS) ([@bib57]; [@bib70]; [@bib90]; [@bib173]; [@bib217]; [@bib218]; [@bib245]; [@bib267]).

Metabolic impairments associated with obesity may contribute to the release of inflammatory mediators (IL-18, IL-1β) due to the stimulation of the NLR (nucleotide-binding oligomerization domain (NOD)-like receptors) family pyrin domain-containing 3 (NLRP3) which forms a cytoplasmic complex known as the NLRP3 inflammasome, with direct modulating role on the innate immune system. This pathway is involved in obesity as well as associated inflammation, and among the endogenous danger signals activating it we can find glucose and ROS. Also, literature data states that IL-18 as well as IL-1β are produced as an effect of TLR (Toll-like receptors)-mediated NF-κB activation, thus pointing out to the interaction of different signalling pathways ([@bib86]; [@bib273]; [@bib307]).

In the light of these pathways, consolidated research is needed to point out in ability of some dietary components, based on the RLRS approach, to reduce the expression of inflammatory molecules and resolve the ROS-inflammation cycle, in order to diminish the risk for long-time comorbidities associated with obesity/metabolic impairments.

3. Microenvironment originating inflammatory cues {#sec3}
=================================================

The extracellular matrices (ECMs), are complex, multi-constituent meshes that surround and support cells in tissues, with a regulatory role in all biological processes, as well as in tissue organization ([@bib124]). The ECMs are composed of fibrillar proteins and proteoglycans, as well as glycosaminoglycans specifically organized as modules or domains. The ECM suprastructure can be envisaged as a "platform" receiving, and simultaneously, delivering a myriad of signals to cells that are crucial to homeostasis, but also contributing to the progression of various pathologies ([@bib253]; [@bib276], [@bib277]). Importantly, the inflammation-mediated alterations in the ECM result in release of active mediators crucial to disease progression ([@bib142]; [@bib196]; [@bib200]). Noteworthy, the effects exerted by remodelled ECM are cell and tissue type dependent exerting thus, specific influence to discrete tissue compartments ([@bib198]).

Recent developments highlighted the importance of ECM remodelling in metabolic disease and obesity as well as the associated inflammation ([@bib239]). Indeed, it was suggested that both the specific remodelling of adipose tissue ECM organization and dysregulated intracellular signalling processes may be correlated with obesity-associated insulin resistance ([@bib106]). The main components of adipose tissue ECM are collagens, fibronectin and laminin ([@bib187]). Minor constituents include osteopontin, hyaluronan (HA), thrombospondins, MMPs, as well as A disintegrin and metalloproteinase domain-containing protein (ADAMs), and contribute significantly to ECM remodelling and the regulation of adipose tissue functions ([@bib162]).

The main characteristic of obesity is an increase in lipid tissue infiltration due to the hypertrophy of existing adipocytes, as well as due to the hyperplasia of adipocytes resulting from *de novo* adipogenesis from precursor stem cells ([@bib246]). Indeed, it was postulated that the ECM, in a spatial as well as temporal manner, regulates adipogenesis ([@bib256]). In addition to adipocyte deposition, a notable migration of macrophages and vascular cells was correlated to changes in the ECM structure. This remodelling leads to the release of active mediators that can affect immune cells' recruitment and activation, facilitating the inflammatory state of lipid tissue. Furthermore, the strong upregulation of obese adipose tissue ECM components, including collagens and osteopontin, was suggested to initiate the necrosis of adipocytes, enhance the infiltration of immune cells, leading to tissue inflammation and metabolic dysfunction ([@bib49]; [@bib239]). Thus, the overexpression of endotrophin, resulted from the cleavage of the α-3 chain of collagen VI (*Col6a3*), facilitates the deposition of fibrotic collagen and initiates adipose tissue inflammation and insulin resistance ([@bib259]). A recent study demonstrated that the expression of MMP14 is strongly upregulated in the adipose tissue of transgenic obese mice. Interestingly, MMP14 proteolytic activity results in the release of endotrophin with concurrent formation of enlarged adipocytes and increase in body weight, altered lipid metabolism and insulin resistance ([@bib157]). Furthermore, Springer et al. recently demonstrated a link between alterations in the ECM of obese women and breast cancer. Thus, enhanced adipose tissue interstitial fibrosis facilitates the generation of M2/M1 type macrophages pattern similar to that of tumour-associated macrophages, as well as the generation of associated inflammatory cues ([@bib257]). Under these conditions a paracrine loop consisting of free fatty acids and TNF-α is established among adipocytes and infiltrating macrophages that enhances inflammation-mediated alterations in the adipose tissue ([@bib81]). Recently, lumican, a small leucine-rich proteoglycan ([@bib199]), was shown to be overexpressed in ECM of subcutaneous fat of insulin resistant obese individuals. Lumican was demonstrated to alter the organization of collagen I, dysregulate adipogenesis and trigger oxidative stress, facilitating the pathology of obesity-associated insulin resistance ([@bib106]). A separate study showed that the effect of lumican was diet-dependent and correlated to adipose tissue inflammation. Indeed, the same authors suggest that the ECM protein lumican could pose a convergent point among the ECM, the glucose homeostasis and the metabolic syndrome ([@bib297]).

Osteopontin, an ECM glycoprotein, excessively secreted by adipose tissue macrophages ([@bib206]) enhances adipose tissue inflammation and facilitates the onset of insulin resistance ([@bib12]). Another important ECM component, the glycosaminoglycan HA, has been strongly correlated to increased inflammatory burden, including cancer-associated ([@bib200]) and sterile inflammation ([@bib142], [@bib143]; [@bib199]). The biologic role of HA is dependent on its size. Thus, high molecular weight HA (HMWHA), physiologically secreted by cells facilitates normal tissue stability ([@bib142]). In contrast, low molecular weight HA (LMWHA) fragments, produced *via* enzymatic action or chemical reactions, are pro-inflammatory and have been characterized as a danger-associated molecular patterns (DAMP) ([@bib142], [@bib143]; [@bib198]). Indeed, the generated LMWHA fragments can trigger a Toll-like receptor 4 (TLR4)/NF-κB signalling pathway to regulate inflammatory genes transcription in immune cells ([@bib142]; [@bib262]). Interestingly, HA levels were increased in various tissues of type-2 diabetes mellius (T2DM), but not in type-1 (T1DM) subjects, and independent of glycaemic control. Taking into account that T2DM, in contrast to T1DM, is linked with systemic inflammation, it was suggested that inflammatory factors and not hyperglycaemia upregulate HA levels ([@bib194]). Importantly, it was demonstrated that the expression of genes involved in the metabolism of HA was positively correlated to the process of adipocyte differentiation ([@bib5]). Recently, it was shown that HA exerts inhibitory effects in vitro regarding adipogenesis of 3T3-L1 cells, whereas downregulating HA prevented insulin resistance and NAFLD correlated to excess deposition of abdominal fat in HFD-feeding C57BL/6J mouse model ([@bib133]). Moreover, treatment of HFD-fed obese mice with a stable hyaluronidase complex, where human recombinant hyaluronidase was Pegylated, was shown to decreases adiposity, adipose tissue inflammation and insulin resistance ([@bib138]).

A hallmark of metabolic diseases is a high NADH/NAD^+^ ratio, originating from excessive electron supply. This dysregulation results in an altered mitochondrial function and sirtuin-3 (SIRT-3) activity, which result in oxidative stress and distorted fatty acid β-oxidation ([@bib56]). Increased ROS production was shown to induce excessive remodelling of the ECM in a pathological milieu ([@bib197]). Thus, oxidative stress induced by high-glucose levels, in rat glomerular mesangial cells, resulted in an increased deposition of collagen IV and fibronectin, through the involvement of the TXNIP-NLRP3 inflammasome signalling ([@bib289]). Importantly, the remodelling of renal ECM is involved in the progression of diabetic nephropathy, one of the most serious complications of diabetes mellitus. Treatment aimed at downregulating ROS generation, such as the utilization of dihydroquercetin (DHQ), an important natural dihydroflavone, attenuated the activation of NLRP3 inflammasome and the subsequent of increased deposition to ECM of renal fibrosis-associated proteins upon exposure of renal cells to high glucose levels ([@bib72]).

These data highlight the complex interactions between the ECM, inflammation, and metabolic diseases. The reorganization of the ECM as well as ECM-originating pro-inflammatory cues needs to be taken account when designing efficient therapy for inflammation associated disease. Dietary measures might constitute important means to mitigating these pathological pathways.

4. Carbohydrate--restricted diets and their effects on inflammation {#sec4}
===================================================================

Postprandial hyperglycaemic spikes are linked to ROS generation and inflammation, as ROS, via the NF-κB pathway, promote the expression of pro-inflammatory molecules such as MCP-1, TNF-α, IL-6, IL-1β, along AP-1, as well as FOXO. These molecules interfere with the insulin signalling pathway, add to the insulin resistance progress ([@bib167]; [@bib290]) and affect blood levels of some inflammatory biomarkers more than chronic hyperglycaemia ([@bib22]; [@bib69]). Healthy diets, based on low glycaemic index food, resulting in a lesser increase of glycemia and lipemia in postprandial settings, induced a lower production of pro-inflammatory molecules ([@bib22]; [@bib69]). In preclinical studies, a strict restriction of carbohydrate intake was shown to promote inflammation and shorten lifespan in senescence-prone mice, increasing IL-6 and IL-1β, compared to diets rich in fats ([@bib113]), with no alteration of serum glucose or insulin versus a standard diet ([@bib201]).

However, a long-term carbohydrate-restricted, high-fat diet promoted a pro-inflammatory state ([@bib114]), impairing glucose ([@bib79]; [@bib114]) and lipid metabolism ([@bib92]), affecting liver ([@bib92]) and pancreatic function ([@bib79]; [@bib114]). A high intake of saturated fats also led to an increase in pro-inflammatory molecules' levels (IL-1β or leptin) ([@bib9]), although a short-term diet enrichment with ketone diesters induced anti-inflammatory effects in NLRP3-mediated inflammatory maladies ([@bib301]). Post-spinal cord injury, a ketogenic diet reduced oxidative stress as well as inflammation, suppressing the NF-κB pathway ([@bib9]; [@bib166]), while activating Nrf2, resulting in lowering TNF-α, IL-1β, IFN-γ expression ([@bib166]). The highlights of these studies are presented in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} .Table 1Clinical studies regarding the effect of high fibre intake on inflammatory markers in obesity and associated pathology.Table 1DesignPopulationDietary interventionOutcomeReferenceRandomized cross-over trial50 Danish subjects with high risk of metabolic syndrometwo 8-week periods of whole grain intake (179 ± 50 g/day)/refined grain (maximum 13 ± 10 g/day of whole grain), divided by a washout period of ≥6 weeks.↓ body weight, serum inflammatory markers (IL-6, CRP)[@bib236]Double-blind, crossover, placebo-controlled, randomized study45 metabolic syndrome patients risk factorsgalactooligosaccharide mixture intervention to increase dietary fibre content, with a 4-wk wash-out period between interventions↓ faecal calprotectin, CRP[@bib285]Randomized controlled trial143 individuals with metabolic syndrome12 weeks of rye and whole wheat was compared with a diet containing the equivalent amount of refined cereal foodsno significant effects on the expression of inflammatory markers\' genes or insulin sensitivity[@bib97]Randomized crossover study19 adults with metabolic syndrome4-week of arabinoxylan and resistant starch enriched diet versus Western-style, low-fibre diet↓ faecal calprotectin, IL-23A and NF-κB[@bib109]Crossover intervention study25 hypercholesterolemic subjects5-week intervention using low fibre and high fibre diet, separated by a 3-week washout.↓ CRP and fibrinogen[@bib134]Randomized controlled trial68 overweight with prediabetes12 weeks of 45 g/d of high-amylose maize (RS2) versus an isocaloric amount of amylopectin (control)↓ TNF-α, no change in insulin sensitivity[@bib219]Randomized controlled trial166 subjects with features of metabolic syndrome4-week using healthy diet (fruits and vegetables, berries, whole-grain products, rapeseed oil, three fish meals per week) compared to an regular Nordic dietControl diet: ↑ IL-1 Ra (versus healthy diet group)[@bib281]Crossover study10 healthy subjectsSubjects received either 910calorie high- carbohydrate/high-fat meal or a standard meal according to American Heart Association (based on fruit and fibre) during the first visit and the other meal during the second visit↑ oxidative stress (bloodlevels of TBARS, LPS, FFA) and proinflammatory markers (TNFα, and IL-1β)[@bib60]Randomized controlled trial28 T2DM patientsSubjects received brown rice (n = 14) or white rice (n = 14) diet for 8 weeks↓ CRP in brown rice group[@bib150]Parallel design, dietary intervention trial104 subjects with metabolic syndrome riskSubjects received Healthy Diet (n = 44), a whole-grain-enriched diet (n = 42) or a control (n = 45) diet,Healthy Diet group: ↓ E-selectin\
Healthy Diet and whole grain group: ↓ CRP[@bib64]Cross-over, randomized, placebo-controlled, double-blind, study12 overweight and obese subjectsSubjects received 20 g/day of inulin (high-fermentable fibre) and cellulose (low-fermentable fibre) for 42 daysIPE: ↓ IL-8 levels (versus cellulose)Inulin: no effect on the inflammatory markers[@bib51]Crossover clinical study18 subjects at low-to-moderate cardiometabolic riskSubjects received breakfast either rich in fibre, unsaturated fatty acids (unSFA) or saturated fatty acids (SFA) for 4 weeksSFA: ↑ IL-1β unSFA: ↓IL-6[@bib186]Interventional diet study21 overweight/obese childrenSubjects were placed on a regimen of low-fat, high-fibre diet and daily exercise for 2 weeks↓ PAI-1, TNF-α, IL-6, IL-8, resistin, insulin, amylin, leptin, and IL-1ra\
↑ adiponectin[@bib129]Randomized, placebo-controlled study31 hemodialysis patientsPatients received either resistant starch or placebo supplementation, for 4 weeks↓ IL-6 and TBARS[@bib83]Randomized controlled clinical trial55 women with T2DMSubjects received 10 g resistant dextrin/day or a similar amount of maltodextrin for 8 weeks↓ IL-6, TNF-α and MDA\
↑ Insulin sensitivity[@bib3]Randomized cross-over double-blind placebo-controlled trial17 obese knee osteoarthritis patientsPatients received freeze-dried strawberries or placebo for 2 periods of 12 weeks with 2 weeks of wash-out↓ TNF-α and 4-HNE[@bib24]Randomized study59 T2DM patientsPatients received metformin, acarbose and either a high fibre or a low fibre diet intervention for 8 weeksLow fibre group: ↓ IL-18[@bib208]Crossover study33 healthy, middle-aged adultsPatients received either high or low in in wholegrain intervention for 6-week periods, separated by a 4-week washout.Whole grain: a slight decrease of IL-10 and CRP[@bib8]Observational study8 subjects with impaired fasting glucosesubjects received (1) high-fibre formula; (2) high-monounsaturated fatty acid formula or (3) control formulaHigh fibre group: ↓ NF-κB in PBMCs[@bib146]Randomized controlled clinical trial60 females with T2DMPatients received 10 g/d resistant starch or placebo for 8 weeks, respectively↓TNF-α, no effect on IL-6 or CRP[@bib93]Crossover clinical trial80 overweight subjectsSubjects received two isocaloric breakfast interventions -one rich in saturated fat and one in unsaturated fatty acids and fibres for 4 weeks with a 2-weeks washout.Fibre group: ↓ IF-γ and TNF-α[@bib186]Observational study49 T2DM femalesPatients received either 10 g/day inulin or maltodextrin/day for 8 weeksInulin: ↓CRP, TNF-α and LPS[@bib66]Randomized controlled clinical trial52 overweight/obese women with T2DMPatients received either 10 g/d of oligofructose-enriched inulin or maltodextrin (control) for 8 weeksoligofructose-enriched-Inulin: ↓ CRP, TNF-α and LPS[@bib67]Randomized crossover clinical trial44 overweight/obese girls 8--15 years oldSubjects received either whole-grain or control for 2 periods of 6 weeks with 4-week washout periodWhole grain: ↓ CRP, ICAM-1 and leptin[@bib108]Table 2Preclinical reports regarding the relationship between carbohydrate intake and inflammation.Table 2DietSpeciesTreatmentObserved effectsReferencesCarbohydrate-restricted dietSenescence-accelerated prone mice (SAMP8)8-week treatment:➢Control: standard chow➢High fat diet group (HFD)➢Carbohydrate-restricted diet group (CRD)CRD: ↑ IL-6 and IL-1β, ↓cecum short-chain fatty acids[@bib113]Scandinavian low-carbohydrate high-fat (LCHF) dietFemale C57BL/6J mice (n = 7/group)4-week treatment:➢standard chow➢LCHF diet (75% fat 20% protein, and 5% carbohydrates)LCHF: no change in glycemia, TG, insulin, or non-esterified fatty acid plasma levels[@bib201]Ketogenic dietSprague-Dawley Rats with spinal cord injury (n = 18/group)4-week treatment:➢ketogenic diet (KD)➢standard diet (SD)➢control (C)KD: ↓ IL-1β, TNF-α, IFN-γ expression[@bib166]Ketogenic dietMale C57BL/6J mice22-weeks diet intervention:➢Control: standard chow➢Ketogenic diet groupKD: ↑ triglycerides, cholesterol, leptin, MCP-1, IL-6, IL-1β,\
↓ α- and β-cell mass[@bib79]Ketogenic versus Western dietC57BL/6J mice12-week treatment:➢very low-carbohydrate, low-protein, and high-fat ketogenic diet (KD)➢high-simple-carbohydrate, high-fat Western diet (WD)➢low-fat, polysaccharide-rich control (C)KD: euglycaemia and hypoinsulinemia + liver lipid accumulation (different pattern compared to WD)\
KD: systemic glucose intolerance, steatosis, cellular injury, endoplasmic reticulum stress (in liver), and macrophage accumulation, maintaining whole-body insulin responsiveness[@bib92]High-saturated fat diet (HFD)male C57BL/6J mice3-week treatment:➢standard chow➢HFD (60% fat 20% protein, and 20% carbohydrates)➢Very HFD (80% fat 16% protein, and 4% carbohydrates)HFD: ↑ leptin, IL-1β[@bib9]Diet supplemented with ketonesKnockout mice model for Muckle-Wells Syndrome and Familial Cold Autoinflammatory syndrome1-week treatment:➢Control: normal chow with 4.5% fat➢Study group: normal chow supplemented with 20% 1,3-butanediol ketone diestersStudy group: ↓ IL-1β release and caspase-1 activity[@bib301]High fat high sucrose diet (HFD)C57BL/6 J (wild type; WT) male mice8-week treatment:➢Young + normal diet (YND)➢Young + HFD (YHFD)➢Old + normal diet (OND)➢Old + HFD (OHFD)HFD led to β-cell failure in aged mice, enhanced expression of pro-inflammatory cytokines and macrophage transformation to a more pro-inflammatory phenotype[@bib114]

On the other hand, long-term diets abundant in highly processed and high glycaemic index products seem also to induce a pro-inflammatory metabolic profile ([@bib99]; [@bib168]). These recent reports suggest that not only the quantity, but also the type of carbohydrates and fats consumed is the major influencing factor of systemic inflammatory status. Thus, clinically, even a 4-day low-carbohydrate diet intervention improved the insulin and fasting plasma glucose levels in T2DM patients ([@bib193]). When comparing low-carb to low-fat diets in diabetics, some older studies reported a similar effects on cardiovascular risk markers ([@bib61]), while more recent ones asserted the beneficial effects of restricting carbohydrates on the systemic low-grade inflammation, reducing IL-6 ([@bib16]; [@bib135]), resistin, leptin ([@bib16]), E-selectin, sICAM ([@bib61]) and increasing adiponectin ([@bib16]). Furthermore, the improvement of systemic inflammatory status was also reported in obese adults, with no T2DM or CVD ([@bib121]).

Switching to a very strict low-carb diet was associated with an increase of systemic inflammation in apparently healthy subjects ([@bib237]), while in subjects with metabolic syndrome or obesity, a short-term ketogenic diet yielded beneficial cardiometabolic effects ([@bib107]; [@bib241]). In T2DM patients, a one-year nutritional ketosis intervention resulted in a lower cardiovascular risk ([@bib31]). Importantly, these beneficial effects are amplified by physical exercises ([@bib7]; [@bib16]; [@bib193]), and by the diet supplementation with nuts ([@bib120]), soy ([@bib139]), or even carefully choosing the types of ingested carbohydrates. In obese and overweight adolescents and adults, a diet based on low glycaemic index food improved inflammation, metabolic as well as cardiovascular risk factors ([@bib238]), while the addition of functional foods resulted in further benefits ([@bib128]). Also, the consumption of complex carbohydrates led to a decline of pro-inflammatory molecules' level in pregnant women ([@bib118]). The results of most recent clinical studies concerning the link between low-carb diet and systemic inflammation are summarized in [Table 3](#tbl3){ref-type="table"} .Table 3Recent reports regarding the relationship between carbohydrate intake and inflammation.Table 3Diet typeDesignPopulationInterventionEffectsRef.Low-carbohydrate versus high-fat dietRandomized crossover study11 T2DM patients4-day diet intervention:➢Group 1: Low-fat low-glycaemic index diet,➢Group 2: Low-carbohydrate high-fat diet➢Group 3: Low-carbohydrate high-fat diet +15-min postmeal walksGlycemia and circulating proinsulin were significantly lower in groups 2 and 3 versus 1;[@bib193]Low-carbohydrate versus low-fat dietRandomized controlled feeding study33 obese T2DM patients8-week diet intervention:➢Normal diet➢Low-carbohydrate diet (LCD)➢Low-fat diet (LFD),➢followed by 12 weeks of high intensity interval training 3 days/week, then a 4-week diet intervention, as presented above.After the 24-week period:\
LCD: ↓ IL-6, resistin, leptin, glucose, insulin, cholesterol, TG, ↑ HDL\
LFD: ↓ TNF-α, LDL, HOMA-IR, ↑ adiponectin[@bib16]Low-carbohydrate versus low-fat dietRandomised controlled trial51 T2DM patients6-month diet intervention:➢Low-carbohydrate diet (LCD)➢Low-fat diet (LFD)LCD: ↓ sICAM, E-selectin\
LFD: ↓ CRP[@bib61]Low-carbohydrate versus low-fat dietRandomised controlled trial51 T2DM patients6-month diet intervention:➢Low-carbohydrate diet (LCD)➢Low-fat diet (LFD)LCD: ↓ IL-1Ra, IL-6[@bib134]Low-carbohydrate versus low-fat dietClinical trial148 obese adults (no diabetes and CVD)12-month diet intervention:➢low-carbohydrate diet -- LCD, n = 75 (\<40 g/day)➢low-fat diet -- LFD, n = 73 (\<30% kcal/day from total fat, \<7% saturated fat)LCD: ↑ adiponectin ↓ICAM[@bib121]Low-carbohydrate + nutsRandomised controlled trial51 T2DM patients3-month diet intervention:➢Low-carbohydrate diet + peanuts: 60 g for men, 50 g for women (LCD-P)➢LCD + almonds: 55 g for men, 45 g for women (LCD-A)Improved glycaemic profile versus baseline, no difference between groups regarding IL-5 serum levels[@bib120]Low-Calorie, Low-Carbohydrate Soy DietParallel randomized clinical trial45 patients with NAFLD8-week diet intervention:➢Group 1: Low-calorie (LC) diet,➢Group 2: LC, low-carbohydrate diet➢Group 3: LC, low-carbohydrate diet + soy (LCS)LCS: ↓ glycaemic indices, CRP[@bib139]Switching to an isocaloric ketogenic diet (KD)Clinical study17 men (BMI: 25--35 kg/m^2^)Transitioning from a normal diet (4 weeks--35% fat, 15% protein, 50% carbohydrate) to 4 weeks of an isocaloric KD (80% fat, 5% carbohydrate, 15% protein)KD: ↑glycerol, free fatty acids, glucagon, adiponectin, gastric inhibitory peptide, TC, LDL, CRP\
↓Fasting insulin, C-peptide, triglycerides and fibroblast growth factor 21[@bib237]Carbohydrate-restricted Paleolithic-based dietRandomized crossover trial12 subjects with metabolic syndrome4-week diet intervention:➢carbohydrate-restricted (\<50g) Paleolithic-based diet + sedentary activity (PD-S)➢PD + high-intensity interval training (PD-Ex)PD-S + PD-Ex: ↓ Glycaemia, TG, fasting insulin, insulin resistance, CRP, TNF-α, IL-6, ICAM-1[@bib107]Low carbohydrate high fat, dietRandomised controlled trial55 obese subjects12-week diet intervention:➢High-fat, low-carbohydrate diet (HFLC) group➢Low-fat, high-carbohydrate diet (LFHC) groupHFLC: ↓ CRP,TG ↑ adiponectin, HDL[@bib241]Nutritional ketosisRandomised controlled trial262 patients with T2DM12-month diet intervention:➢Nutritional ketosis (NK, n = 262)➢Control group, normal diet (n = 87)↓ CRP[@bib31]Moderate-carbohydrate versus low-fat dietRandomised controlled trial122 overweight and obese adults6-month diet intervention:➢Group 1: moderate-carbohydrate and high-glycaemic index (GI) diet (HGI), n = 37➢Group 2: a moderate-carbohydrate and low-GI diet (LGI), n = 36➢Group 3: a low-fat and high-GI diet (LF), n = 31LGI vs LF: ↓ fasting insulin, ↑ HOMA\
No significant differences among groups regarding lipid profiles, inflammatory and metabolic risk markers (IL-6, MCP-1, Leptin, ICAM-1).[@bib136]Low-glycemic-index dietRandomised controlled trial90 subjects12-week diet intervention:➢isocaloric control diet (50% of energy from carbohydrate, 35% from fat, 15% from protein)➢low-glycaemic-index diet (LGI) (60% from carbohydrate, 25% from fat, and 15% from protein)➢LGI, rich in functional foods (LGI + FF) (60% from carbohydrate, 25% from fat, and 15% from protein)LGI + FF vs. control: ↓CRP, TNF-α\
LGI + FF vs. LGI: ↑ adiponectin[@bib128]Low glycaemic index dietRandomised controlled trial50 obese and overweight adolescent girls10-week diet intervention:➢Healthy nutritional recommendation diet (HNR)➢Low glycaemic index diet (LGI)↓ IL-6, CRP[@bib238]Low- carbohydrate high-fat diet versus higher-complex carbohydrate lower-fatRandomized controlled feeding study12 overweight and obese women with gestational (31 weeks) diabetes mellitus31-week diet intervention:➢control conventional low-carbohydrate, higher-fat diet (LCHF, 40% carbohydrate, 45% fat, 15% protein; n = 6)➢higher-complex carbohydrate/lower-fat diet (CHOICE, 60% carbohydrate, 25% fat, 15% protein; n = 6)CHOICE: ↓ expression of proinflammatory genes (IL-1β, TNF- α)[@bib118]Regular dietObservational study95 postmenopausal womenParticipants classified according to CRP - lower or ≥3 mg/L. Sedentary lifestyle was described by walking ≤6000 steps/day; diet was evaluated using a validated food frequency questionnaire.CRP was higher for women with sedentary lifestyle and higher glycaemic load[@bib7]Low-fructose dietComparative study28 patients with chronic kidney disease6-week of low-fructose diet (LFD), followed by 6 weeks of regular diet↓ insulin, CRP sICAM (decrease of insulin and sICAM persistent, while CRP did not when resuming regular diet)[@bib36][^1]

So, adding high-fiber and exercise to a low-index carbohydrate diet has beneficial effects on inflammatory profile of T2DM and obese patients while low-carb and low-fat diets induce the same type of effects on cardiovascular risk markers of diabetes patients.

5. Mediterranean diet and the impact on inflammation {#sec5}
====================================================

The Mediterranean diet (MD) is based on the dietary pattern found in the Mediterranean basin (Greece, southern regions of Italy and Spain), and includes high amounts of fresh vegetables and fruits, seeds, nuts, along with olive oil and whole grain cereals. Milk, cheese, yogurt, eggs, fish and poultry are consumed in moderate amounts, as is wine (especially red), with low amounts of red meat and sugary deserts ([@bib177]; [@bib265]). This diet is abundant in minerals and vitamins, antioxidants and phytochemicals ([@bib265]). Although several of its components exerted beneficial actions, most likely their combined synergistic effects contribute to reducing the systemic inflammatory burden ([@bib265]). Some authors posit that MD exerts a hormetic effect, similar to caloric restriction, highlighting the Nrf2 pathway, regulating the pro-/anti-inflammatory processes equilibrium ([@bib178]). Epigenetic regulation was also hypothesized, especially due to components found in nuts and extra virgin olive oil, which were reported to alter the methylation of some genes related to inflammation, metabolism and signal transduction ([@bib15], [@bib14]).

In healthy subjects, even one MD-style meal was shown to reduce the expression of pro-inflammatory molecules ([@bib62]), with no differences between sexes regarding effects on systemic inflammatory status ([@bib25]). In elderly individuals, a MD intervention lead to lower glycoxidative impairment ([@bib165]) and inflammatory response ([@bib45]; [@bib302]), paralleled to a diet based on saturated fatty acids ([Fig. 2](#fig2){ref-type="fig"} ).Fig. 2Diets rich in proteins, lipids and carbohydrates induce the production of pro-inflammatory molecules that lead to the activation of several inflammatory pathways including JAK/STAT pathway, NF-Kβ pathway and MAPK kinase cascade. These pathways lead to oxidative stress, as wells as, COX-2, TNF-α, and interleukins production via transcriptional regulation ultimately leading to chronic inflammation. Oxidative stress either directly or via metabolic dysfunctions causing e.g insulin resistance, as well as the rest of the inflammatory molecules as a result of unhealthy diet promote the onset of several chronic diseases including CVD, neurodegenerative diseases, autoimmunity, pulmonary diseases and are-related frailty; (NF-kβ -- nuclear factor kappa-light-chain-enhancer of activated B cells heterodimer, consisting of p50, p65 and IkBα proteins; STAT3 -- Signal transducer and activator of transcription 3; ERK/MAPK -- mitogen-activated protein kinases; JNK -- c-Jun N-terminal kinases; COX-2 -- cyclooxygenase 2; TNF-α -- Tumour necrosis factor alpha; IL-1/6/8 -- interleukin 1/6/8).Fig. 2

A marked reduction of inflammatory molecules (C reactive protein -- CRP, E-selectin, P-selectin, TNF-α, IL-1β, IL-6) and of mRNAs of pro-inflammatory genes was reported in overweight and obese individuals which adhered a classic or modified MD ([@bib26]; [@bib176]; [@bib214]; [@bib232]; [@bib268]). Furthermore, in diabetics and patients with high cardiovascular risk, MD determined a significant reduction of serum levels of CRP, interleukins and adhesion molecules ([@bib48]; [@bib50]; [@bib170]; [@bib180]). In a group of asthmatic children, MD supplemented with 150g cooked fish twice a week resulted in significantly improved pulmonary function and markedly increased docosahexaenoic acid (DHA) levels and improved omega-6 to omega-3 ratio ([@bib215]). The recent clinical trials addressing the relationship between MD and inflammation are summarized in [Table 4](#tbl4){ref-type="table"} .Table 4Recent reports concerning Mediterranean diet and inflammation.Table 4**Design**PopulationInterventionEffectsReferenceFeeding study25 subjectsOne-meal intervention:➢Tocopherol-enriched Mediterranean meal➢Western high-fat meal↓ expression of inflammation-related genes[@bib62]Controlled feeding study35 men and 27 women➢4-week MD interventionMD induced the same type of response regarding hs-CRP both in males and females[@bib25]Randomized Controlled Trial1142 subjects12-month diet intervention:➢MD-like NU-AGE diet + vitamin D3 (10 μg/day)➢Control groupSlowed the decline of bone mineral density only in the femoral neck in subjects with osteoporosis[@bib131]Randomized Controlled Trial20 elderly subjects4-week diet intervention:➢MD + coenzyme Q10 (MD-Q10)➢MDDiet rich in saturated fatty acids (SFAD)MD, MD-Q10: ↓ expression of p65, IKK-b, MMP-9, IL-1b (versus SFAD)\
MD-Q: marked decrease of P65 and IKK-b (versus the other diets)[@bib302]Randomized Controlled Trial20 elderly people4-week diet intervention:➢MD + olive oil (MD-O)➢diet rich in saturated fatty acids (SFAD) low-fat, high-carbohydrate diet enriched in n-3 PUFA (LFHC-PUFA)MD-O: ↓ expression of inflammation-related genes (versus SFAD: p65, MCP-1; versus LFHC-PUFA: p65, TNF-α)[@bib45]Randomized Controlled Crossover Trial20 elderly subjectsisocaloric diets for successive periods of 4 weeks in a crossover design: MD, MD + CoQ, Western diet↓ AGE, RAGE[@bib165]Randomized Controlled Trial34 male overweight subjects4-week diet intervention:➢Ketogenic MD (KMD)KMD + omega-3 (KMD-O3)KMD: ↓ TNF-α\
KMD-O3: ↓ IL-1β, IL-6, TNF-α, ↑ adiponectin[@bib214]  Controlled feeding study50 overweight and obese subjects13-week diet intervention: Caloric restriction, MD + dietary supplementation↓ CRP (versus baseline)[@bib268]Clinical Trial90 subjects with abdominal obesity2-month diet intervention:➢MD, using olive oilControl groupMD: ↓ CRP, P-selectin, E-selectin (versus baseline)[@bib232]Clinical Trial40 subjects with metabolic syndrome8-week diet hypocaloric MD intervention↓ mRNA associated with the regulation of inflammatory genes[@bib176]Randomized Controlled Trial36 subjects with metabolic syndrome3-month MD intervention↓ CRP, insulin[@bib26]Randomized Controlled Trial24 T2DM patients3-month diet intervention:➢MD, using olive oilLow fat diet (LFD)MD: ↓ IL-6, ICAM-1, ↑ GLP-1 stimulated insulin secretion[@bib50]Randomized Controlled Trial215 T2DM (newly diagnosed)12-month diet intervention:➢MDLow fat diet (LFD)MD: ↓ CRP (37%), ↑ adiponectin (43%)[@bib170]Randomized Controlled Trial56 coronary heart disease patients6-month diet intervention:➢MDLow fat diet (LFD)↓ dietary inflammatory index (including IL-1b, IL-4, IL-6, IL-10, TNF-α, CRP)[@bib180]Randomized Controlled Trial164 subjects with high cardiovascular risk12-month diet intervention:➢MD + 50 mL extra virgin olive oil (MD-O)➢MD + 30 g nuts (MD-N)Low fat diet (LFD)MD-O: ↓ CRP (45%), IL-6 (35%), sICAM-1 (50%), P-selectin (27%)\
MD-N: ↓ CRP (45%), IL-6 (35%)\
(versus LFD)[@bib48]

In recent years, the effects of a diet similar to MD started to be investigated: the Nordic diet (ND). Similarly, ND is based on fruits, especially berries, and vegetables, fish, whole grains, and includes low amounts of processed red meat and is almost lacking saturated fats. As olive oil is specific for the Mediterranean basin, the ND includes canola oil ([@bib155]; [@bib169]). Literature reports are reviewed elsewhere ([@bib155]) and although scarce, they indicated that ND exerted anti-inflammatory effects, as it was able to reduce the serum levels of CRP ([@bib64]; [@bib155]).

Dietary interventions based on Mediterranean/Nordic style induce positive effects on both inflammation and redox stress, both in healthy patients and in those with metabolic impairments (diabetes mellitus, obesity, metabolic syndrome). The hormetic effects induced at the level of the immune system is pointed out by the positive results induced by MD on people with inflammatory phenomena impacting the respiratory system, including children with asthma.

6. Polyunsaturated fatty acids in the inflammation hallmark {#sec6}
===========================================================

Literature data mentions two main groups of polyunsaturated fatty acids (PUFAs), of plant or animal origin: omega-3 (n-3) and omega-6 (n-6). The most discussed molecules of each group are α-linolenic acid (ALA) and linoleic acid (LA), respectively. Functionally, notable among the omega-3 fatty acids are the eicosapentaenoic acid (EPA) and the docosahexaenoic acid (DHA) ([@bib43]), although docosapentaenoic acid (DPA) is materializing as an important member of the n-3 family ([@bib141]). In human diets, the two essential PUFAs, LA, and ALA are usually derived from plant sources (such as seeds, nuts, seed oils and derived products), as only plants synthesize them ([@bib41]). Linseeds and their oil habitually contain 45--55% of n-3 PUFAs, mainly ALA, whereas soybean or rapeseed oil, and walnuts only about 10% ALA ([@bib151]).

Another important food source of n-3 PUFAs are fatty fish and also other seafood or derived products, known as "fish oils". All these products contain significant quantities of DPA, EPA and DHA, as a result of plankton and algae consumption and not as a result of endogenous synthesis ([@bib228]). Noteworthy, the dominant PUFAs in fish, as well as fish oils, vary between species. For instance, cod liver oil contains more EPA than DHA, whereas tuna oil has a higher content of DHA ([@bib42]). One portion of fish could bring into diet between 200 and 300 mg n-3 PUFAs, while 1 g of fish oil contains almost 30% EPA and DHA, highlighting the importance of diets including seafood. In the absence of fish or derived products, the daily intake of n-3 PUFAs in most adults is below 200 mg/day ([@bib183]). As plants produce much more LA than ALA, the former is the most customary PUFA in Western diets ([@bib32]). The daily dietary intake of ALA is 0.5--2 g, while of LA greatly increased in the last 50--60 years, along with a significant change of n-6/n-3 ratio ([@bib44]), reaching as high as 20 in some Western-type diets ([@bib41]).

LA and ALA share a common metabolic pathway in animals and humans ([@bib228]). LA is metabolised by Δ6-desaturase to γ-linolenic acid (GLA), and later by elongase and Δ5-desaturase to arachidonic acid (ARA), while ALA is converted by the same enzymes into EPA, subsequently to DPA then, finally, to DHA. The rate of transformation from ALA to EPA and later to DHA is affected by several factors such as age, sex, or genetics ([@bib19]). In addition, levels of ALA, LA and DHA are affected by chronic diseases as shown in a study comparing lipid levels between patients with autoimmune diseases and healthy controls ([@bib275]).

The conversion of dihomo-gamma-linolenic acid (DGLA) to ARA is regulated by insulin and ARA/EPA ratio is a sensitive marker for insulin resistance, a common denominator of most chronic inflammatory diseases. In a study of healthy adult volunteers AA to EPA ratio and the ARA precursor -- DGLA, significantly changed with age ([@bib274]). The metabolism of n-6 PUFAs is more prevalent compared with n-3 PUFA, due to the fact that LA is much more common in actual diets ([@bib32]), although ALA, and not LA, is the preferred substrate for Δ6-desaturase ([@bib43]).

Noteworthy, LA, ARA, EPA and DHA are important constituents of membrane phospholipids and have important roles in membrane function, which greatly influences cell activity ([@bib38]). The proportion of PUFAs found in the membrane is dependent on cell type, dietary intake and metabolism ([@bib44]). For example, in healthy subjects receiving a typical Western diet, the percentages of DHA, EPA, and ARA, in mononuclear cells were 2.5, 0.5 and, respectively, 20% of total fatty acids ([@bib41]).

The effects exerted by n-3 PUFAs are arbitrated either by the fatty acid molecules or by their bioactive metabolites from one of the three categories: protectins, resolvins, and maresins. The E-resolvins (such as E1, E2, and E3), are produced from EPA, while the D-series resolvins including D1, D2, D3, D4 and D5, neuroprotectins/protectins (NPD1/PD1), and the maresins (MaR1), are biosynthesized from DHA ([@bib59]; [@bib249]). The biotransformation of n-3 PUFAs involves the COX and LOX pathways. S-resolvins, S-protectins, and S-maresins are produced from DHA and EPA via LOX pathway, while R-resolvins and R-protectins are derived from aspirin-activated COX-2 or cytochrome P450 metabolic transformation of DHA and EPA ([@bib43]). In most cell types, ARA is highly predominant and exhibits direct links to inflammatory pathways, since it constitutes the substrate for enzymes such as cytochrome P450, cyclooxygenase or lipoxygenase, yielding mediators from the eicosanoid family. Indeed, the synthesis of pro-resolving mediators is increased when the diet is rich in n-3 PUFAs. Thus, in healthy subjects, a daily supplement for 3 weeks of 1 g DHA and 1.5 g EPA, quantified measurable levels of resolvins D1, D2, and 17-R resolvin D1 (\>25 pg/ml plasma) ([@bib179]). In obese women treated for 3 months with a daily supplement of 1.8 g EPA and DHA, DHA-derived pro-resolvins mediators were measured and found to be increased (RvD1 and RvD2 \> 60 pg/ml plasma) ([@bib226]).

6.1. Inflammatory-resolving effects induced by PUFAs {#sec6.1}
----------------------------------------------------

Nowadays, the mechanisms of action by which n-3 PUFAs regulate the inflammatory processes are widely investigated. The suppression of inflammation by n-3 PUFAs is associated with one of the following mechanisms (1) competitive inhibition of n-6 PUFA pathway; (2) modification of cell membrane composition; (3) affecting the formation of rafts or (4) direct anti-inflammatory effect of their bioactive metabolites (resolvins, protectins, and maresins) ([@bib228]).

It has been demonstrated that the dietary supplementation with DHA and EPA from fish increases in a dose-response manner the content of DHA and EPA in the cell inflammation-responsible phospholipids ([@bib44]); increased content of DHA or EPA in different tissues, such as adipose tissue or heart was also observed in correlation with their intake ([@bib43]) ([Fig. 3](#fig3){ref-type="fig"} ).Fig. 3The effect of omega-3 fatty acids and polyphenols in the regulation of the inflammatory response. Omega-3 fatty acids inhibit the inflammatory response by inhibiting PGE2 which promotes inflammation and NF-κB either directly, via the interaction with the transcriptional factors PPARs, or by inhibiting TLR2/4 which normally activates NF-κB. Moreover, omega-3 fatty acids regulate inflammation by activating MAPK and GPR120 which in turn inhibits inflammation. Polyphenols inhibit the inflammatory response by directly inhibiting NF-κB, or via the PPARs. They also promote fatty acid b-oxidation and inhibit VCAM-1, ICAM-1, MAPK pathway, PGE2 and COX-2 that all promote chronic inflammation (PGE2 --prostaglandin 2; NF-κB -- nuclear factor kappa-light-chain-enhancer of activated B cells; PPARs -- peroxisome proliferator-activated receptors; TLR2/4-- toll-like receptor; MAPK -- mitogen-activated protein kinase; GPR120 -- G-protein coupled receptor 120; VCAM-1 -- vascular cell adhesion molecule 1; ICAM-1 -- intracellular cell adhesion molecule 1; COX-2 -- cyclooxygenase 2; TNF-α -- tumour necrosis factor alpha; MCP-1 -- monocyte chemoattractant protein 1; AMPK -- AMP kinase).Fig. 3

These n-3 PUFAs frequently substitute n-6 PUFAs like ARA, resulting in decreased availability of ARA for eicosanoid synthesis. EPA also inhibits ARA metabolism as a competitive substrate for COX-2, decreasing prostaglandin E2 (PGE2) production. In rats, dietary supplementation with ALA inhibits PG biosynthesis from ARA, while equivalent quantities of ALA and LA decreased up to 40% n-6 PUFAs incorporation in phospholipids ([@bib44]). Furthermore, Rees et al. observed that a daily EPA intake of 2.7 g or 4.05 g for 3 months decreases the PGE2 production by lipopolysaccharide-stimulated mononuclear cells, while a lower dose of 1.35 g did not. EPA was integrated in a linear dose-dependent manner into mononuclear cell phospholipids and plasma. This study suggested a daily threshold in the range of 1.35--2.7 g EPA for the anti-inflammatory action ([@bib234]).

Besides decreasing production of PGE2, DHA and EPA are also substrates for the biosynthesis of lipid derivatives, but the EPA-derived mediators as series-3 prostaglandins (PGD3) or series-5 leukotrienes are typically less biologically potent, having a lower ability to interact with relevant eicosanoid receptors ([@bib43]). For example, EPA-derived leukotriene B5 (LTB5) is almost 100 times less active as a leukocyte chemoattractant than ARA-derived LTB4 ([@bib44]). However, in some cases, EPA-derived mediators have similar potency with ARA-derived mediators. It appears that EPA-derived PGD3 inhibits the effect of the ARA-derived PGD2, due to a stronger interaction with the DP1 receptor compared to PGD2 ([@bib286]). In other cases, EPA-derived mediators exhibited a similar magnitude of effect (e.g. inhibition of TNF-α production by blood monocytes) ([@bib75]).

6.2. Molecular targets of PUFAs {#sec6.2}
-------------------------------

There are several pharmacological studies suggesting molecular targets for the anti-inflammatory effects of n-3 PUFAs and their metabolites: PPAR-γ, GPR120, CMKLR1 (known as ChemR23), BLT1(leukotriene B4 receptor 1), GPR32 and ALX/FPR2 ([@bib125]). Thus, resolvins E1 and D1 exhibited a higher affinity for these receptors compared to EPA or DHA. Chem R23 and BLT1 are receptors of resolvin E1, while GPR32 and ALX/FPR2, bind to lipoxin A4 and resolvin D1 with high affinity. GPR120 was reported to be a receptor of EPA and DHA (EC50 \~ 1--10 μM), while ALX/FPR2 to annexin I and lipoxin A4 ([@bib249]). Furthermore, some studies on GPR120 KO mice suggest that n-3 PUFAs that activate GPR120, interact with β-arrestin 2, and suppress NF-κB activation and macrophage-mediated inflammatory responses ([@bib209]). However, it is important to highlight that the *in vivo* anti-inflammatory effects of n-3 PUFAs in humans are minor and might only occur at high n-3 PUFA levels, it was demonstrated in vitro that BSA-conjugated n-3 PUFA are incapable of activating GPR120 ([@bib125]).

DHA and EPA are weaker agonists of PPAR-γ (EC50 \~ 10--100 μM), while their oxidized metabolites (such as protectin D1) are much more potent ([@bib300]). Also, ALA or ARA has a similar potency to DHA or EPA for on PPAR-γ, and higher for PPAR-α ([@bib43]). As PPAR-γ activation reduces inflammatory responses, *via* the NF-κB pathway, this mechanism could partially explain the anti-inflammatory effects of n-3 PUFAs. Furthermore, n-3 PUFAs were reported to suppress NF-κB activation in a PPAR-γ-independent manner by binding to TLR-4 under certain conditions ([@bib125]). Taking into account all these reports, it looks like three mechanisms are employed by n-3 PUFAs to suppress inflammatory signalling via NF-κB: (1) preventing NF-κB nuclear translocation via PPAR-γ activation, (2) interfering with membrane activation of NF-κB via TLR4 and (3) interaction with GPR120 initiating an anti-inflammatory signalling cascade ([@bib43]).

Resolvin D1 is a potent agonist to GPR32 and ALX/FPR2 (EC50 = 8.8 pM and 1.2 pM), while Resolvin E1 strongly binds to Chem R23 (Kd = 4.5 nM), reducing IL-12 production ([@bib152]) and is a partial agonist to BLT1, so it induces NF-κB activation via BLT1, inhibiting neutrophil migration ([@bib13]). For the other resolvins, protectins or maresins, the molecular targets are not yet identified.

Isolated n-3 PUFAs and their bioactive mediators were extensively examined in animal models of colitis or arthritis or using specific transgenic models. n-3 PUFAs and RvD1, RvD5, PD1 and MaR1 administration proved effective in animal models of colitis, decreasing inflammation and chemically induced colonic damage. The beneficial effects are, in all cases, correlated with the reduction of ARA-derived mediators in the colonic mucosa ([@bib33]; [@bib52]; [@bib98]; [@bib172]). Surprisingly, aspirin-triggered resolvin D1 (AT-RvD1) displayed a stronger anti-inflammatory effect than RvD2 in experimental colitis, through lipoxin A4 receptor (ALX) activation ([@bib30]). Furthermore, n-3 PUFAs as fish oil has shown not just anti-inflammatory effects in peripheral tissues, but several beneficial effects in obesity-induced animal models, such as improved lipid profile, decreased hepatic steatosis and insulin resistance ([@bib20]; [@bib223]). Indeed, beneficial effects of DHA and EPA in adipose tissue were reported in mice fed a high-fructose diet, including modulating pro- and anti-inflammatory markers and ameliorating adipocyte abnormalities. The effects were significantly higher for DHA compared to EPA ([@bib21]).

Additionally to anti-inflammatory effects, correlated with down-regulation of IL-6 and TNF-α expression in liver, n-3 PUFAs also exhibited triglyceridemia lowering effects in diabetic rats via modulation of PPAR-α ([@bib71]; [@bib96]). Additionally, Lee et al. demonstrated that a diet with a high n-6/n-3 PUFAs ratio (\~9) induced dysbacteriosis of the gut microbiota in obesity-induced T2DM or high-fat-diet treated rats, while a low ratio (\~3) enhanced blood glucose homeostasis ([@bib156]). The outcomes of the most recent animal studies are summarized in [Table 5](#tbl5){ref-type="table"} .Table 5Mittigating inflammation in animal model studies -- effects of PUFAs.Table 5Tested compound(s)Animal modelMain anti-inflammatory findingsReferencesn-3 PUFA (fish oil or mix fish and olive oil or flaxseed oil)TNBS colitis↓IL-1β; IL-12p70; ↓IL-6; ↓TNFα; ↑PGE3,↑ TXB3; ↑ LTB5[@bib33]TNBS colitis↓colon iNOS, ↓COX-2 expression, ↓IL-6, ↓LTB4, ↓TNFα production[@bib52]DSS colitis↓TNF-α; ↓ COX-2; ↑anti-inflammatory PG;[@bib251]Carrageenan induced inflammation↓TNF-α; ↓ IL-6[@bib303]STZ- diabetic rats↑ gene expression PPRγ; ↓ NF-κB activity[@bib96]STZ- diabetic rats↓TNF-α; ↓ IL-6[@bib156]STZ-NIC diabetic rats↑ PPAR-α only by flaxseed oil; both (flaxseed oil and fish oil):↑ D5 and D6 desaturases; ↓TNF-α; ↓ IL-6;[@bib71]STZ-NIC diabetic rats↑ renal SOD-1; ↑ GPx-1 expression; ↑ CAT; ↓ renal AGEs formation ↓AGE protein expression; ↓ IL-6; ↓ NF-κB expression[@bib130]STZ-NIC diabetic rats↓ IL-1β; ↓TNFα; ↓IL-6; ↓IL-17 A; ↓MDA[@bib308]Wistar rats↓ IL-6; ↓ TNF-α; ↓IL- 10 receptor[@bib223]C57BL/6 mice↓ NF-κB expression; ↓ IL-6; ↓ TNF-α[@bib20]EPA monoglicerideDSS colitis↓PMN infiltration; ↓ NF-κB activity; ↓IL-1β; ↓TNF-α; ↓ IL-6; ↓expression of COX2 in colon[@bib188]ALATNBS colitis↓ IP-8, ↓ LTB4, ↓ colon NF-κB DNA binding activity[@bib112]EPA vs. DHAhigh-fructose fed C57BL/6J mice↓ TNF-alpha and IL-6 gene expressions; ↓MCP-1 pERK and NFkB protein expressions[@bib21]EPA free fatty acidAPC^Min/+^ FAP model↓ COX-2 expression; ↑ EPA tissue uptake; ↓ lipid peroxidation[@bib87]CAC model C57BL/6J mouse↓PGE2; ↑ EPA tissue uptake[@bib222]Endogenous conversion n-6 into n-3 PUFACAC model\
Fat-1 mouse↓ COX-2 expression; ↓ NF-κB activity; ↓PGE2[@bib110]Chronic arthritis\
Fat-1 mouse *vs* WT mouse↓ IL-17; ↑mRNA expression of Foxp3 (in Fat-1 mouse)[@bib147]AT-RvD1DSS colitis/TNBS colitis↓PMN infiltration; ↓ NF-κB activity and mRNA expression; ↓IL-1β; ↓MIP-2; ↓mRNA expression of VCAM-1, ICAM-1[@bib30]Adjuvant-induced arthritis↓TNF-α; IL-1β[@bib161]RvD2DSS colitis↓IL-1β; ↓ murine KC (IL-8 human homolog)[@bib46]TNBS colitis↓PMN infiltration; ↓ NF-κB activity and mRNA expression; ↓IL-1β; ↓MIP-2; ↓mRNA expression of VCAM-1, ICAM-1[@bib30]RvE1DSS colitis↓PMN infiltration; ↓TNF-α; ↓mRNA expression of IL-6, TNFα, IL-1β[@bib126]Collagen-induced arthritisNo statistical significant effect on TNF-α[@bib65]RvD5DSS colitis↓PMN infiltration; ↓TNF-α; ↓ IL-6; ↓IL-1β;[@bib98]MaR1DSS colitis/TNBS colitis↓PMN infiltration; ↓ NF-κB activity; ↓IL-1β; ↓TNF-α; ↓ IL-6; ↓mRNA expression of ICAM-1[@bib172]PD1DSS colitis↓PMN infiltration; ↓IL-1β only partially[@bib98][^2]

6.3. n-3 PUFAs effects in humans {#sec6.3}
--------------------------------

In healthy subjects, different daily doses of EPA and DHA up 1800 mg, administered up to 5 months, showed no significant effects on the CPR, IL-6, and TNF-α ([@bib17]; [@bib89]; [@bib190]). A comparable conclusion was drawn by other authors. According to Rangel-Huerta\'s meta-analysis, consumption of 900 mg--2000 mg n-3 PUFAs does not change inflammatory biomarkers in healthy subjects ([@bib233]). On the other hand, doses between 1250 and 2400 mg n-3 PUFA for 4 months lowered inflammation in sedentary and overweight middle-aged and older adults ([@bib145]). Lp-PLA2, another anti-inflammatory marker was significantly reduced by a high dose of EPA (1800 mg) but not by DHA ([@bib17]). Interestingly, only DHA modified the lipid profile by decreasing postprandial triglyceride concentrations and significantly increasing low-density lipoprotein cholesterol, with no significant changes in inflammatory biomarkers ([@bib17]). In elderly subjects, daily supplementation with 2500 mg EPA and DHA, for 8 weeks, significantly reduced the plasma levels of fatty acids, IL-1β, IL-6, and TNF-α ([@bib261]). Similarly, in obese patients who received different doses of combined n-3 PUFAs (380--1290 mg DHA and 360--460 mg EPA) for 2--3 months, the intervention reduced the expression of proinflammatory genes in adipocytes and systemic inflammatory markers sVCAM-1, CRP, IL-6, and TNF-α ([@bib127]; [@bib226]). Furthermore, other relevant metabolic findings connected with n-3 PUFA treatment were reported, such as decreasing fasting triglycerides and insulin ([@bib4]; [@bib226]) or decreasing fasting blood glucose in obese diabetics ([@bib80]). Partially, these results are in line with the modest reduction in waist circumference and body-weight found in a meta-analysis ([@bib29]). The authors indicated that the effect regarding waist circumference produced by fish intake or fish oil supplementation and might be greater in men than in women. The beneficial effect in overweight and obese adults concerning waist circumference and triglyceridemia was confirmed by two other meta-analyses ([@bib76]; [@bib305]).

As most of the cited trials utilize a mixture of DHA and EPA which may mask the effects of each compound, the individual effects of DHA or EPA in obese patients were also investigated, but the results were inconclusive. A significant reduction in serum IL-18 and adiponectin with DHA than with EPA was observed in one study ([@bib4]), while no differences between DHA and EPA in the expression of pro-inflammatory genes were observed in another study ([@bib284]).

In patients with impaired glucose metabolism and T2DM in almost all studies, none of the combined EPA and DHA doses had any effect on IL-6, IL-1β, CRP, VCAM, and sICAM ([@bib54]; [@bib185]; [@bib243]). Further, no effects on glycated haemoglobin (HbA1c) ([@bib243]; [@bib298]), insulin ([@bib54]) or lipid profile ([@bib282]) were found. Only [@bib282], observed that HbA1c decreased significantly, and fasting blood glucose increased after n-3 PUFAs treatment for 24 weeks, but no other key findings. An overview of the most recent human studies where the inflammatory biomarkers as a result of PUFAs treatments, were assessed as the main outcome, is summarized in [Table 6](#tbl6){ref-type="table"} .Table 6Clinical effects induced by PUFAs.Table 6Intervention(n)Main anti-inflammatory findingsOther relevant findingsReferences**Healthy subjects**4-month intervention:➢1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)➢2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)➢placebo138↓TNF-α and ↓ IL-6 for both low and high dose groups↓ n-6:n-3 ratio for both low and high dose groups[@bib145]6-week intervention:➢600 mg EPA/day➢1800 mg EPA/day➢600 mg DHA/day➢placebo121No effect on hsCRP, TNF-α, IL-6, VCAM-1, ICAM-1 and fibrinogenOnly High dose EPA ↓ Lp-PLA2;\
DHA: ↓ TG; ↑ LDL\
No effect of low dose EPA[@bib17]18-week intervention:1000 mg EPA + 400 mg DHA/day vs. placebo261No effect on serum CRP and IL-6--[@bib190]5-month intervention:➢300 mg EPA + DHA/day➢600 mg EPA + DHA/day➢900 mg EPA + DHA/day➢1800 mg EPA + DHA/day➢placebo125No significant effect on IL-6 or CPR;\
Marginal effect on TNF-α observed at the highest dose (1800 mg)Higher RBC DHA was associated with lower TNF-α concentrations.[@bib89]8-week intervention:2500 mg EPA + DHA/day vs. placebo35↓IL-6, IL-1β and TNFα--[@bib261]**Obese patients**2-month intervention:➢460 mg EPA and 380 mg DHA/day➢control (butter fat)55↓IL-6\
↓ inflammatory gene expression in adipose tissue\
↑release of anti-inflammatory eicosanoids in adipose tissue↓TG[@bib127]3-month intervention: 360 mg EPA and 1290 mg DHA/day vs. placebo59↓ VCAM-1; ↓ PECAM-1; ↓ hsCRP No effect on IL-6↓ TG; ↓insulin.\
No effect on TC, HDL, LDL, NEFA, FBG[@bib226]10-week intervention:➢2700 mg EPA/day➢2700 mg DHA/day➢placebo154↓ IL-18 and ↑ adiponectin (DHA \> EPA)\
No difference between EPA and DHA regarding effect on CRP, IL-6, TNFα↓ TG; ↑ HDL (DHA \> EPA)\
↑ LDL by DHA only in men[@bib4]10-week intervention:➢2700 mg EPA/day➢2700 mg DHA/day➢control (corn oil)154EPA: ↑TRAF3 and PPARα expression\
DHA: ↑ PPARα and TNFα expression both ↓CD14 expressionNo significant difference between EPA and DHA.[@bib284]12-week intervention:➢LSM + 600 mg EPA + DHA/day➢LSM➢placebo29LSM & n-3 PUFA ↑ adiponectin in comparison to LSM\
No effect on IL6No effect on leptin, LIF, follistatin, BDNF, and fasting triacylglycerol[@bib247]**Hypertensive and/or diabetic obese patients**8-week intervention:300 mg EPA + 200 mg DHA/day vs. control64↓CRP↓ FBG; ↓TG[@bib80]**Impaired glucose metabolism patients**6-month intervention:1800 mg EPA/day vs. placebo107↓ CRP but similar effects in placebo↑ HDL and ↓fasting TG; No effect on HbA1c and FBG[@bib243]9-month intervention:2388 mg EPA +1530 mg DHA/day vs placebo36No effect in IL-1B, IL-6, hsCRP, ICAM and VCAMNo effect on FBG, insulin, HOMA-IR.[@bib54]**Type 2 diabetes mellitus**12-week intervention: 4000 mg (42% EPA + 25%DHA)/day vs. placebo91No significant effect on CPR↓ TG; No effect on LDL, HDL, HbA1c[@bib298]12-week intervention: 900 mg EPA/day vs. placebo24No effect on CRP, IL-6 and TNFα↑ HDL and ↑ total cholesterol[@bib185]8-week intervention: 2700 mg EPA + DHA/day84↓ IL-2 and ↓ TNFα\
No effect on CRPNone tested[@bib171]12-weeks intervention:➢1000 mg EPA/day➢1000 mg DHA/day➢placebo60No effect on serum CRP and MDANo effect on body weight, BMI or fat mass[@bib18]24-week intervention:➢2800 mg EPA + DHA + 15 mg pioglitazone/day➢2800 mg EPA + DHA + placebo/day➢5 mg pioglitazone/day➢placebo60No effect on SOD, TBARS, GSSG/GSH↑ HbA1c; ↑FBG\
No effect on TG, TC, HDL, LDL, NEFA, Leptin, Adiponectin[@bib282]3-month intervention: 1000 mg EPA + 1000 mg DHA/day vs. placebo74No effect on hsCRP, IL-6, TNF-α, ICAM-1, VCAM-1No effect on insulin, HbA1c, adiponectin, leptin, and lipid levels[@bib227]**Metabolic syndrome**90-day intervention:➢1800 mg EPA+ 1200 mg DHA + 10 mL extra virgin oil/day➢1800 mg EPA + 1200 mg DHA + placebo/day➢10 mL extra virgin oil/day➢placebo102No effect on CPRNo effect on TG, TC, HDL, LDL, FBG, insulin, HOMA-IR[@bib283]**Inflammatory bowel disease**8-week intervention: 3400--3600 mg n-3 PUFA (as salmon)/day12↓ CPR, ↑ anti-inflammatory fatty acid index\
No effect TNF- α, MDA↑ n-3 PUFAs,↑ n-3/n-6 ratio in plasma and rectal biopsies; No effect on the fecal calprotectine[@bib104]90-day intervention: 2000 mg EPA/day20↑ IL-10 expression; HES1, SOCS3, and KLF4↓ fecal calprotectine\
Partially redressed microbiota composition[@bib230]6-month intervention: 1000 mg EPA/day vs.placebo60No effect on CPR↓ fecal calprotectine[@bib244][^3]

6.4. Dietary recommendations of n-3 LC-PUFA {#sec6.4}
-------------------------------------------

Currently, the recommended daily intake of n-3 PUFAs varies as regarding expert committees, ranging from 250 to 500 mg for healthy adults ([@bib88]). The European Food Safety Authority\'s (EFSA) recommendation is 250 mg/day n-3 PUFAs (EPA and DHA) for adult males and non-pregnant females, and supplementation of 100--200 mg/day of DHA in pregnancy ([@bib78]). For children less than 2 years old, the daily recommendation corresponds to 100 mg DHA, while for children more than 2 years and in adolescents, the daily recommendation is similar to that for adults ([@bib78]). The upper daily value of acceptable for EPA and DHA consumption has been set at 2000 mg, but higher doses used in clinical trials did not induce adverse effects ([@bib233]).

There are also some additional recommendations in patients with high and extremely high fasting-triglyceride levels. The American Heart Association (AHA) recommends a daily intake of 500 mg--1000 mg DHA and EPA in patients with borderline levels (150--199 mg/dl), 1000--2000 mg in patients with high levels, and 2000--4000 mg in patients with very high triglyceride levels (\>500 mg/dl) ([@bib151]). Importantly, further research should be conducted before any definitive daily recommendation or on the routine use of n-3 PUFAs in other chronic inflammatory diseases.

Studies show that n-3 PUFAs do not impact in a positive manner the metabolic profile of healthy subjects and induce variable effect on diabetes mellitus cases (no important effects on inflammation but a constant ability to increase the HDL level); on the other hand, a reduction of inflammation is obese and ageing patients as well as in those with metabolic syndrome.

7. Role of polyphenols in counteracting inflammatory phenomena {#sec7}
==============================================================

Literature data demonstrates that there are approximately 8000 different polyphenolic structures, classified into more than ten classes depending on structural characteristics. Regardless of their differences in chemical behaviour, they are all characterized by having an aromatic ring carrying one or more hydroxyl groups ([@bib34]; [@bib68]). The polyphenolic molecules originating from diet are involved as key components in counteracting inflammation, mitigating oxidative stress and protecting endogenous compounds from oxidative lesions, regulating the metabolism and promoting a protective phenotype, in improving the endothelial function as well as the platelet function, among several other beneficial actions ([@bib137]; [@bib189]; [@bib205], [@bib204]).

Polyphenols are key dietary components extensively studied for their involvement in preventing CVD, comorbidities of metabolic syndrome, malignancies, etc, all these diseases having an important etiological inflammatory component. For example, a central stage in the expansion of atherosclerosis is dyslipidemia, which together with increased ROS formation leads to LDL oxidation, which was correlated with the activation of pro-inflammatory pathways in the vascular wall. Likewise, it is well established that ROS and pro-inflammatory molecules generate a microenvironment predisposing to endothelial dysfunction. The increased expression of adhesion molecules (VCAM-1, ICAM-1, E-selectin) favours the adherence of monocytes to the endothelium and their infiltration within the vascular wall. As a result, of monocyte diapedesis pro-inflammatory molecules are released (TNF-α, IFNγ, MCP-1), NFκB is up-regulated, interleukins (IL-6 and IL-8) and metalloproteinases (MMPs) are synthesized ([@bib102], [@bib101]; [@bib111]; [@bib159]; [@bib160]; [@bib280]).

7.1. Cellular effects {#sec7.1}
---------------------

Polyphenols interfere with the inflammatory process in multiple pathways. For example, they alter the enzymatic processes involved in the proliferation and activation of B- and T-cells, as key components of the inflammatory pathway (by inhibiting tyrosine and serine-threonine protein kinases). Likewise, polyphenols blunt the synthesis of pro-inflammatory mediators such as cytokines, chemokines (IL-8, IL-6, TNF-α, VCAM-1 and ICAM-1), and angiogenic factors, NF-кB or iNOS. Further, an inhibitory effect on several pro-inflammatory enzymes was reported, such as COX-2, MAPK or protein kinase-C (PKC) ([@bib6]; [@bib94]; [@bib122]). Thus, studies performed on macrophages proved that resveratrol inhibited the IFN-γ-induced NO production and down-regulated the IFN-γ inducible genes. In this respect, resveratrol decreased STAT1 activation (an important transcription factor for IFN-γ-induced genes) and hindered JAK-2 activation ([@bib53]).

Experimental studies arguing the involvement of polyphenols in mitigating inflammation are either performed on cell line models, animal models or have direct clinical implications. In a study exposing human endothelial cells to the effect of *Negroamaro* and *Primitivo* extracts or pure compounds - stilbenes (*trans*-resveratrol, *trans*-piceid), hydroxycinnamic acids (*p*-coumaric, caffeic, and caftaric acids) flavonols (kaempferol, quercetin, myricetin) -- before stimulation with lipopolysaccharide (LPS), an inhibition in the expression of adhesion molecules was demonstrated. The anti-inflammatory effect was sustained by a reduction of VCAM-1, ICAM-1, E-selectin, MCP-1 and macrophage colony-stimulating factor (M-CSF), ROS intracellular levels with a correlated attenuation of NF-κB and AP-1 activation. *Trans*-resveratrol also significantly reduced the endothelial expression and release of M-CSF. All tested compounds reduced the adhesion of monocytes to stimulated endothelial cells, this being a key element in the development of atherosclerosis ([@bib40]). The treatment of CCD-18Co myofibroblasts cells with red wine extract reduced mRNA levels of ICAM-1, VCAM-1, NF-κB, and PECAM-1, induced by LPS the anti-inflammatory mechanism being dependent on miR-126 ([@bib10]).

Another study tested the effects induced by a mixture of four main catechins found in green tea (epicatechin -- EC, epigallocatechin -- EGC, epigallocatechin gallate -- EGCG, epicatechin gallate -- GCG), as well as each one alone, on neutrophils isolated from healthy subjects. The catechin compounds induced anti-inflammatory effect (reduction of IL-1β and IL-6, TNF-α, HOCl synthesis and mieloperoxisase), together with the stimulation of antioxidant enzyme activities and Nrf2, along calcium release as well as increased phagocytic capacity, thus proving anti-inflammatory and immunomodulatory actions ([@bib175]). In a separate study, EGCG reduced ICAM-1, NF-ĸB and IĸB expressions and reduced ROS levels upon TNF-α-induced inflammation in human retinal pigment epithelial cells. The results suggest the possible therapeutic involvement of EGCG in blocking TNF-α-mediated eye inflammation ([@bib263]). Moreover, in a study evaluating the effect of epicatechin and catechin on arachidonic acid-activated platelets and, respectively, on platelet-HUVEC interaction, the tested compounds induced a reduction of sICAM1, sVCAM1, and sE-selectin levels, as well as an increase of NO bioavailability, proving an anti-inflammatory effect and the ability to counteract endothelial dysfunction, but only when platelets were harvested from peripheral artery disease patients and not from healthy subjects ([@bib47]).

Ellagic acid (EA) was tested for its ability to inhibit MIF-induced chemotactic migration of PBMCs, showing a failure to inhibit this response when PBMCs were stimulated with MIP-1α, but high specificity for MIF-induced effect ([@bib242]). Chlorogenic acid exerted a dose depended anti-inflammatory effect showed by the reduction of IL-1β, TNF-α and IL-6 levels as well as the inhibition of NO synthesis and expression of COX-1 and iNOS in LPS-stimulated murine macrophages and microglial cells ([@bib123]).

An in vitro experiment evaluated the results induced by various flavonoids on the arachidonic acid release from rat neutrophils; kaempferol, luteolin, quercetin and amentoflavone reduced the inflammatory response and inhibited the activity of β-glucuronidase and lysozyme ([@bib264]). Furthermore, the positive outcome of *Brassica oleracea* extracts (water and methanol respectively) for CVD risk were examined; for this purpose, HUVECs were exposed to the extracts (24 h) and then to TNF-α stimulation. Exposure to the extracts from *Brassica oleracea* significantly reduced the TNF-α induced expression of E-selectin, ICAM-1 and VCAM-1 ([@bib154]). Another study demonstrated the capacity of extracts from Mango (*Mangifera indica* L.) to counteract TNF-α effects on HUVECs, through the inhibition of IL-6, IL-8, COX-2 and ICAM-1, while restoring the expression of eNOS usually down-regulated by TNF-α ([@bib192]). Interestingly, in an animal model, for example, supplementation of standard chow with cacao phenolic compounds in apolipoprotein E-deficient mice, lead to an anti-inflammatory effect justified by a reduction of VCAM-1 and ICAM-1 expressions, a decrease of oxidative stress markers and a reduction of cholesterol accumulation in plaque compared to control ([@bib195]). Likewise, propolis (green, red or brown) treatment induced a reduction of MCP-1, VCAM, PECAM, FGF, PDGF, VEGF, MMP-9 and upregulated tissue inhibitor of metalloproteinases 1 (TIMP-1) in initial atherosclerotic lesions in LDL receptor gene knockout mice fed a diet rich in cholesterol for inducing atherosclerotic lesions; only red propolis upregulated heme oxygenase 1 (HO-1) and TIMP-1 in advanced atherosclerotic lesions ([@bib58]).

7.2. Anti-inflammatory potential of polyphenols in humans {#sec7.2}
---------------------------------------------------------

The anti-inflammatory effects induced by polyphenols in human studies with dietary interventions and weight related outcomes are heterogeneous, as summarized from recent literature ([Table 7](#tbl7){ref-type="table"} ). Thus, in a clinical study with double-blind, randomized, cross-over design, the effect of a commercially available polyphenols rich extract was tested, the study including patients having more than two metabolic risk factors. Results showed a reduction of MCP-1 and MIF, but not of other markers of CVD risk (CRP, IL-6, HDL, adiponectin and oxidized LDL) ([@bib35]). In a separate clinical study with cross-over design, overweight patients consumed a high-carbohydrate, moderate-fat meal supplemented with strawberry/placebo juice. The anthocyanin supplementation blunted the postprandial inflammatory response (reduced CRP level) induced by the high fat diet and reduced the postprandial insulin response ([@bib77]). Furthermore, a double-blind study focused on hypercholesterolemia subjects, receiving a purified anthocyanin mixture, resulted in a reduction of their CRP, sVCAM-1 and IL-1β levels. Similar results were obtained for HepG2 and porcine iliac artery endothelial cells exposed to the same purified anthocyanin mixture (reduction of LPS-induced VCAM-1 secretion) ([@bib309]). Patients with early atherosclerosis, received simple or EGCG-enriched olive oil. Independent of EGCG addition, olive oil reduced inflammatory markers and endothelial dysfunction (sICAM, white blood cells, monocytes, lymphocytes and platelets) ([@bib294]).Table 7Clinical data regarding the efficacy of polyphenols on inflammatory phenomena.Table 7DesignPopulationType of interventionInflammatory outcomeReferenceRandomised, double-blind, cross-over study34 subjects with two or more metabolic risk factors4-week intervention: 500 mg polyphenols/day vs. placebo↓MCP-1 and MIF, unchanged levels of HDL, adiponectin, CRP[@bib35]Cross-over study24 overweight adultshigh-carbohydrate, moderate-fat meal together with a strawberry beverage (SB) or placeboSB:↓ CRP and postprandial insulin[@bib77]Randomised, double-blind150 hypercholesterolemic subjects24-week intervention: 640 mg purified Anthocyanin/day↓ CRP, sVCAM-1 and IL-1β[@bib309]Randomised, double-blind52 patients with early atherosclerosis,4-month intervention: 30 mL olive oil or 30 ml of EGCG-supplemented olive oil↓ sICAM, white blood cells, monocytes, lymphocytes and platelets[@bib294]Single-centre, randomised, two-arm, double-blinded, placebo-controlled study36 pre-hypertension patients, randomized to control or treatment groups6-week intervention: grape seed extract, 150 mgx2/day↓BP (SBP, DBP)\
↑ fasting insulin and insulin sensitivity\
No change of sICAM-1[@bib216]Single blinded crossover trial38 patients with untreated mild hypertension8-week intervention: 300 mL/day cold-pressed 100% chokeberry juice and 3 g/day chokeberry powder↓IL-10 and TNF-α[@bib164]Randomized, double-blind, placebo-controlled clinical trial50 hyperlipidemic patients4-week intervention: *V. arctostaphylos* fruit extract x2/dayno effects on HDL and CRP\
↓ total cholesterol, LDL-C, TG, MDA[@bib255]Placebo controlled study20 study subjects and 19 placebo4-week intervention: 361 mg polyphenols and 120 mg vitamin C x2/dayNo significant effects on apolipoproteins, adiponectin, CRP, ICAM-1, E-Selectin or t-PA[@bib191]Placebo controlled study16 trained cyclists7-day intervention: 30 mL of Montmorency tart cherry concentrate x 2/day↓lipid hydroperoxides, IL-6 and hsCRP[@bib27]Double-blind crossover study49 healthy male subjects with APOE genotype8-week intervention: 150 mg/day quercetin or placebo (3 phases, three-week washout periods)↓ waist circumference and postprandial SBP, moderately increased levels of TNFα[@bib221]Randomised, double-blind, placebo-controlled, cross-over trial18 healthy volunteersOne-tine administration of 51 mg of oleuropeine↓of IL8 production[@bib163]Cross-sectional study1997 femalesFrequency questionnaires assessment of total intake of flavonoidsHigher anthocyanin and flavone intake were associated with significantly lower peripheral insulin resistance\
Higher anthocyanin intake was also associated with lower CRP concentrations\
Higher anthocyanin-rich intake was associated with lower insulin and inflammation[@bib132]Randomized, controlled dietary study27 subjects with metabolic syndrome400 g fresh bilberries/days vs. control diet↓ CRP, IL-6, IL-12,[@bib149]

The effects of grape seed extract on pre-hypertension patients were tested. Results of the study in question, showed a reduction of blood pressure (both systolic and diastolic), with improved fasting insulin and insulin sensitivity after 6 weeks of supplementation, but no significant change in sICAM-1 plasma concentration ([@bib216]). Furthermore, in a single blinded crossover trial including patients with untreated mild hypertension, cold-pressed chokeberry juice and dried chokeberry powder induced a reduction of IL-10 and TNF-α levels ([@bib164]).

On the other hand, there are studies that do not confirm the positive effects of natural compounds on inflammatory markers regarding cardiovascular risk, especially on CRP, even if they prove to yield other beneficial outcomes (for example, on LDL). Thus, Soltani et al. examined the effects of a *Vaccinium arctostaphylos*fruit extract on hyperlipidemic adult patients and even if no significant effects were observed regarding HDL and CRP, a significant reduction of total cholesterol, LDL, triglycerides and malondialdehyde (MDA) levels was obtained ([@bib255]). Furthermore, Mullan et al. showed that administering a vitamin C and polyphenol-rich beverage didn\'t induce a reduction of metabolic or inflammatory markers (apolipoproteins, CRP, ICAM-1, E-selectin) ([@bib191]).

Results regarding the effect of polyphenols on inflammation were obtained not only in metabolically impaired patients, but also in healthy subjects. Thus, in a placebo-controlled study, the effect induced by Montmorency tart cherry concentrate on the inflammatory and redox status markers in subjects simulating road cycle racing was examined. Trained cyclists received the concentrate or placebo for 7 days, after which their oxidative stress and inflammatory markers (IL-6 and CRP) were reduced, highlighting the ability of the tested extract to improve the stress response in physical exercise conditions ([@bib27]).

Furthermore, in a study with crossover, double-blind design, 49 healthy males with APOE genotype received 150 mg/day quercetin or placebo for 8 weeks, in three phases, separated by three-week washout periods. Quercetin administration led to a decrease of waist circumference and postprandial systolic blood pressure, as well as a moderately increased levels of TNFα ([@bib221]). In a separate study with cross-over, double-blind, randomized, placebo-controlled design including 18 healthy subjects, the effect of oleuropeine (51 mg) on a single occasion was tested. Blood of the subjects was collected and cells were stimulated with LPS, showing a significant decrease of IL-8 production ([@bib163]).

Flavonoid-rich products have also been discussed for their beneficial effect on insulin resistance-related metabolic complications possibly via the upregulation of genes involved in insulin sensitivity ([@bib82]). In a recent review, the beneficial effect of flavonoid-rich products in a cross-sectional study including 1997 females aged 18--76 years, the correlation between the total flavonoid intake as well as their subclasses (assessed from food questionnaires) and insulin resistance/inflammation was evaluated. Results showed higher anthocyanin and flavone intake were associated with significantly lower peripheral insulin resistance and CRP concentrations ([@bib132]). In a randomized controlled dietary study, results showed that consuming a high anthocyanins diet is associated with the reduction of CRP, IL-6, IL-12, and LPS concentrations indicating a positive effect on the long term cardiometabolic risk ([@bib149]).

According to literature data, polyphenols blunt the inflammatory response in clinical setting, thus reducing the cardio-vascular risk factors for hypertensive, obese or diabetes mellitus patients. Positive effects on inflammation and redox stress markers were also obtained in healthy subjects and, moreover in trained athletes, who seem to benefit from the metabolic point of view from receiving polyphenols supplements.

Just a small number of published studies investigated if n-3 PUFAs may interact with the polyphenols and if a combined diet may have an enhanced beneficial impact. Until now only the beneficial effects on HDL-levels (as a "surrogate" for the anti-inflammatory effect) were identified ([@bib2]; [@bib11]; [@bib37]).

In an 8-week randomized controlled dietary study on overweight patients, a combined diet of high polyphenols and marine PUFAs- diet showed beneficial, although non-additive effects on plasma triglycerides. Also, the reduction in oxidative stress (measured by urinary 8-isoprostane) was observed, probably as an effect of polyphenols. A negative interaction between PUFAs and polyphenols was observed for some variables (chylomicron cholesterol and apo B-48 in large VLDLs), which suggest a possible kinetic interaction between PUFAs and polyphenols ([@bib11]). This kinetic finding is also in line with some preclinical data that suggested that dietary polyphenols interact with the metabolism of n-3 PUFAs and increase blood EPA and DHA level ([@bib266]).

Recently, in a three monocentric, parallel-arm, double-blind, randomised, dietary intervention trial, 250 mg DHA and 320 mg grape anthocyanins administered as bioactive-enriched foods, for 4 weeks, had positive effects on serum triglyceride or HDL levels ([@bib37]). These results are partially in line with a later cross-sectional analysis in the Korean population that suggested beneficial effects exhibited only in men by high amounts of proanthocyanidins or n-3 PUFAs on HDL levels. In addition, n-3 PUFAs intake increased polyphenols uptake ([@bib2]).

In conclusion, large-scale cohort studies with a combined diet PUFAs + polyphenols are needed to confirm the limited available data and to investigate possible additive effects.

8. Metabolic disorder and inflammation in COVID-19 {#sec8}
==================================================

Metabolic disarray and inflammation are important factors in the pathogenesis of acute diseases. COVID-19, severe respiratory disease, is an adverse clinical outcome of the ongoing severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic ([@bib74]; [@bib100]; [@bib252]), and has recently been correlated to obesity-dependent inflammation ([@bib220]). Indeed, in its most severe form, it entails a bilateral interstitial pneumonia requiring intensive care unit (ICU) ventilation support and has concomitant high mortality rate due to and multi-organ failure. Clinical reports have demonstrated that the most common comorbidities are CVD, hypertension and T2DM, age also being an important risk factor ([@bib103]; [@bib306]). Lifestyle-associated factors, such as smoking, have also been associated with rapid disease progression ([@bib85]; [@bib182]; [@bib270]). A recent US study indicates that obesity is an underappreciated risk factor for COVID-19 ([@bib140]). The authors found, in a cohort of 265 hospitalized patients, that age and the body-mass index (BMI) were inversely correlated with risk, hence indicating that younger obese patients were more likely to be admitted to hospital. Kass et al. concluded that a higher prevalence of obesity in each population will result in a higher COVID-19 incidence in younger individuals than previously reported. In addition to a mechanical impediment of ventilation, obesity was correlated with lower immune response to viral infection ([@bib119]). Moreover, besides obesity, metabolic disarray and inflammation were suggested to contribute to COVID-19 pathogenesis ([@bib220]). Indeed, specific fat-resident regulatory T cells (Treg) and enhancement of TH17 (T-cell sub-lineage)-biased immunity ([@bib229]; [@bib295]) could be positively correlated to COVID-19 prevalence and increased mortality risk in obese individuals ([@bib220]; [@bib254]). The "obese" pattern of immune cells subtypes was correlated to increased secretion of pro-inflammatory mediators including IL-6, IL-23/IL-17, TNF-α and macrophage inflammatory protein-1α ([@bib258]). Importantly, these inflammatory mediators were proved to disrupted tight junctions of the respiratory epithelium, which facilitates pathogen entry ([@bib296]).

COVID-19 is impacting to a greater extent the patients having underlying metabolic impairments (diabetes mellitus and/or obesity), as WHO is pointing out. On the other hand, increased levels of inflammatory markers cytokines with pro-inflammatory outcomes constitute predictors of adverse outcome in COVID-19 patients ([@bib254]).

Thus, reducing the inflammatory pathways, through the long-term employment of lifestyle changes (dietary measures, smoking cessation, moderate but constant physical activity, etc) could contribute to a better reaction of the immune system when affected by aggressive pathogens, such as SarsCov2. Improving diet (such as adding polyphenols, PUFAs, fibres, etc) can contribute to a reduction of inflammation, thus increasing the chances for a better response of patients affected by the virus ([@bib39]; [@bib231]; [@bib293]).

9. Conclusions {#sec9}
==============

Diet can play a major part in regulating various cellular pathways, as one is simultaneously and continually exposed to a myriad of ingested substances, which, in their minute doses can yield important long-term effects and influence the development of certain maladies, with their cumulative effects still being underestimated. Real-life risk simulation (RLRS) strategies are powerful tools for assessing not only the toxicological implications of joint effects for several molecules, but also their collective beneficial role as nutraceuticals in our diet intake. These kinds of analyses are important, as studies which separately assess the cellular and metabolic effects of certain compounds can posit their detrimental or protective actions and their potency, and thus can lead to erroneous conclusions regarding their long-term habitual consumption in lower, non-pharmacological doses, but alongside numerous other chemicals ([@bib116]; [@bib174]; [@bib271]). This type of approach will certainly play an important part in one of the most important health struggles nowadays, the prevention of NCD, and could prove itself beneficial even in the context of the present viral outbreak, since inflammation is the key component of the severe phenomena associated with the COVID-19 respiratory complications. There is an intense need for RLRS studies integrating dietary information with the inflammatory response in order to evaluate if the usual components of normal diet could contribute to regulating the immune response and reduce the sensitivity to complications.
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[^1]: ICAM -- intercellular adhesion molecule-1; HOMA -- homeostatic model assessment of β cell function; MCP-1 -- Monocyte chemotactic protein-1.

[^2]: CAC -- colitis associated cancer; CAT -- catalase DSS -- dextran sulfate sodium; GPx -- glutathione peroxidase NIC -- Nicotinamide; PD -- protectin; SOD -- superoxide dismutase; STZ -- Streptozotocin; TNBS -- trinitrobenzene sulphonic acid; EPA -- Eicosapentaenoic Acid; DHA -- Docosahexaenoic Acid; TNF -- α-Tumour Necrosis Factor alpha; LTB -- Leukotriene, PPAR -- peroxisome proliferator-activated receptor; COX -- cyclooxygenase; AGE -- advanced glycation end products; TXB -- Thromboxane; PG -- prostaglandins; ICAM -- Intercellular Adhesion Molecule; VCAM -- Vascular Cell Adhesion molecule; IL -- Interleukin; NF-κB, nuclear factor kappa B; PMN -- polymorphonuclear leukocyte; MIP-2 --macrophage inflammatory protein 2; IP-8 -- Isoprostane-8; Foxp3 -- Forkhead box P3; pERK -- protein kinase RNA-like endoplasmic reticulum kinase; MCP-1 -- Monocyte chemoattractant protein-1; murine KC -- murine chemokine.

[^3]: EPA -- Eicosapentaenoic Acid; DHA -- Docosahexaenoic Acid; PG -- Prostaglandins; LTB -- Leukotriene; TNF-α -- Tumour Necrosis Factor alpha; IL -- Interleukin; CRP -- C-Reactive Protein; ICAM -- Intercellular Adhesion Molecule; VCAM -- Vascular Cell Adhesion molecule; hsCRP -- high sensitive C reactive protein; IL1RN -- interleukin-1 receptor antagonist protein; LSM -- lifestyle modification; NF-κB -- nuclear factor-kappa B); PPAR -- peroxisome proliferator-activated receptor; TRAF3 -- TNF Receptor Associated Factor 3; Lp-PLA2 -- lipoprotein-associated phospholipase A2; PECAM -- platelet and endothelial cell adhesion molecule; COX -- cyclooxygenase; LOX -- lypoooxigenase; TBARS --thiobarbituric acid substances; SOD -- superoxide dismutase; GSH -- glutathione peroxidase; MDA -- malonyldialdehyde; HOMA-IR -- homeostasis model assessment of insulin resistance index; HES1 -- transcription factor HES1; SOCCS3 -- suppressor of cytokine signaling 3; KLF4 -- Kruppel-like factor 4; HbA1c -- Glycated haemoglobin; RBC -- red blood cell; BDNF -- Brain-derived neurotrophic factor; CD14 -- cluster of differentiation 14; NEFA -- Non-esterified fatty acids; TC -- total cholesterol; TG -- Triglycerides; LDL -- low-density lipoproteins; HDL -- high-density lipoproteins; FBG -- fasting blood glucose; LIF -- leukocyte inhibitory factor.
